The PPARγ agonists rosiglitazone and pioglitazone exert beneficial effects in several aspects of PH including: suppression of pro-inflammatory cytokines such as TGF b [58] and metalloprotease [59], suppression of angiotensin-II induced hypertension, and reduction of endothelin-1 levels [48,60,61,62]. The gene discussed is PPARG; the disease is Hypertension.